[1]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419-426.
 WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus: a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(05):419-426.
点击复制

125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
27
期数:
2018年05期
页码:
419-426
栏目:
肿瘤介入
出版日期:
2018-05-25

文章信息/Info

Title:
125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus: a meta- analysis of its clinical effectiveness and safety
作者:
王 龙 张 勇 王亚运 彭 为 郑鹏飞 程志斌
Author(s):
WANG Long ZHANG Yong WANG Yayun PENG Wei ZHENG Pengfei CHENG Zhibing
Division I, Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, Gansu Province 730030, China
关键词:
【关键词】 肝细胞肝癌 门静脉癌栓 125I粒子 经导管动脉化疗栓塞
文献标志码:
A
摘要:
【摘要】 目的 系统评价125I放射性粒子联合经导管动脉化疗栓塞(TACE)治疗肝细胞肝癌(HCC) 伴发门静脉癌栓(PVTT)的有效性与安全性。方法 计算机检索PubMed、EMbase、Cochrane Library、Web of Science、CNKI、CBM、Wan Fang Data、VIP等数据库中125I放射性粒子植入联合TACE治疗HCC伴PVTT的临床对照研究文献,检索时限均自建库至2017年3月。2名评价员独立筛选文献、提取资料并评价纳入文献偏倚风险,采用RevMan 5.3软件进行meta分析。结果 共9篇文献911例患者符合纳入标准,其中3篇随机对照试验(RCT)文献和6篇回顾性文献。Meta分析结果显示,125I粒子联合TACE试验组控制疾病总有效率明显高于对照组(OR=2.58,95%CI=1.46~4.57,P=0.001);术后3个月(OR=7.40,95%CI=3.52~15.57,P<0.000 1)、6个月(OR=4.41,95%CI=3.19~6.11,P<0.000 1)、12个月(OR=4.72,95%CI=3.35~6.64,P<0.000 1)累计生存率均明显高于对照组;术后肝功能不全(OR=0.33,95%CI=0.13~0.82,P=0.02)和消化道出血(OR=0.39,95%CI=0.19~0.80,P=0.009)并发症发生率明显低于对照组。但两组术后转移率(OR=0.82,95%CI=0.46~1.46,P=0.50)和不良反应(发热、恶心、呕吐、白细胞减少等)发生率差异均无统计学意义。结论 HCC伴PVTT患者经125I放射性粒子联合TACE治疗安全有效,1年生存率明显提高,同时降低肝功能不全和消化道出血并发症发生率。受文献数量和质量限制,上述结论尚需高质量、大样本前瞻性RCT研究加以验证。

参考文献/References:

[1] Fomer A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379: 1245- 1255.
[2] Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein tumor thrombosis[J]. Clin Mol Hepatol, 2015, 21: 115- 121.
[3] Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus[J]. Surg Today, 2014, 44: 219- 226.
[4] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53: 1020- 1022.
[5] Stang A. Critical evaluation of the Newcastle- Ottawa scale for the assessment of the quality of nonrandomized studies in meta- analyses[J]. Eur J Epidemiol, 2010, 25: 603- 605.
[6] Li CX, Xu H, Bao- Shan H, et al. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine- 125 seed[J]. Cancer Biol Ther, 2011, 12: 865- 871.
[7] 吴林霖, 罗剑钧, 颜志平, 等. 门静脉支架及经动脉药物治疗栓塞联合或未联合血管内植入碘-125粒子条治疗肝癌合并门静脉主干癌栓的比较[J]. 中华肝脏病杂志, 2012, 20: 915- 919.
[8] 张子寒, 罗剑钧, 颜志平, 等. 血管内近程放疗联合支架植入及经动脉化疗栓塞治疗肝细胞肝癌合并门脉主干癌栓[J]. 复旦学报·医学版, 2016, 43: 1- 8.
[9] 方主亭, 颜志平, 罗剑钧, 等. TACE联合与未联合腔内125I粒子条置入治疗肝癌伴广泛性门静脉癌栓[J]. 中华介入放射学电子杂志, 2013, 1: 8- 13.
[10] 曾德筠. TACE联合125I放射性粒子治疗原发性肝癌合并门静脉癌栓的研究[J]. 齐齐哈尔医学院学报, 2014, 35: 2519- 2521.
[11] 翁志成, 杨维竹, 江 娜, 等. CT引导下125I放射性粒子植入治疗肝癌门静脉癌栓的疗效评价[J]. 介入放射学杂志, 2010, 19: 535- 539.
[12] 蒋 丽, 韩东明, 胡鸿涛, 等. 125I粒子植入联合肝动脉化疗栓塞术预防原发性肝癌合并门静脉癌栓消化道出血[J]. 中华放射学杂志, 2016, 50: 784- 788.
[13] 邵海波, 马腾闯, 牛 猛, 等. 碘125粒子联合肝动脉化疗栓塞术治疗原发性肝癌合并门脉分支癌栓疗效分析[J]. 临床军医杂志, 2016, 44: 377- 381.
[14] 魏 嵬, 张 波, 万茂林, 等. TACE+门静脉支架联合血管内植入碘-125粒子链治疗肝癌合并门静脉主干癌栓的临床疗效观察[J]. 临床放射学杂志, 2016, 35: 1585- 1589.
[15] 孙军辉, 周坦洋, 张岳林, 等. 门静脉支架联合125I粒子链植入序贯肝动脉灌注化学疗法栓塞术治疗肝癌伴门静脉癌栓[J]. 中华消化杂志, 2014, 34: 25- 29.
[16] Sun JH, Zhang YL, Nie CH, et al. Effect of liver cirrhosis on percutancous selective portal vein embolization for primary liver cancer[J]. Zhonghua Yi Xue Za Zhi, 2013, 93: 3831- 3834.
[17] 田玉龙, 刘瑞宝, 刘 岩, 等. 双导向技术引导下125I粒子植入治疗肝癌合并门静脉癌栓[J]. 介入放射学杂志, 2015, 24: 785- 788.
[18] 杜可朴, 周志刚, 高剑波, 等. 放射性125I粒子植入联合TACE治疗原发性肝癌合并门静脉癌栓[J]. 临床放射学杂志, 2014, 33: 916- 919.
[19] 黄 宁, 杨维竹, 江 娜, 等. TACE联合经皮125I粒子植入序贯治疗肝癌伴门静脉主干癌栓临床研究[J]. 临床放射学杂志, 2014, 33: 1416- 1420.
[20] Jeong SW, Jang JY, Shim KY, et al. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis[J]. Gut Liver, 2013, 7: 696- 703.
[21] 余天柱, 罗剑钧, 颜志平. 血管内近程放疗与序贯三维适形放疗治疗门静脉主干癌栓的疗效对比[J]. 介入放射学杂志, 2017, 26: 787- 792.
[22] Qin QH, Huang BS, Tan QX, et al. Radiobiological effect induced by different activities of 125I seed brachytherapy in a hepatocellular carcinoma model[J]. Int J Clin Exp Med, 2014, 7: 5260- 5267.
[23] Liu Y, Liu R, Wang P, et al. Percutaneous implantation of 125I seeds for treatment of portal vein tumor thrombosis in hepatocellular carcinoma[J]. Med Oncol, 2015, 32: 214.
[24] 冉 琳, 任伯绪. 125I粒子组织间近距离放射治疗肝癌的现状与进展[J]. 介入放射学杂志, 2012, 21: 876- 878.

相似文献/References:

[1].关于召开“全国肝癌介入治疗研讨会”的通知[J].介入放射学杂志,1995,(04):200.
[2]张   磊,陆骊工,李   勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
 ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(05):968.
[3]李海伟,刘 静,李 森.125I粒子植入与伽玛刀治疗门脉癌栓的疗效对比[J].介入放射学杂志,2014,(08):702.
 LI Hai wei,LIU Jing,LI Sen..125Iodine seed implantation and gamma knife for the treatment of portal vein tumor thrombosis in hepatocellular carcinoma: comparison of therapeutic efficacy[J].journal interventional radiology,2014,(05):702.
[4]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
 YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history: initial experience in seven cases[J].journal interventional radiology,2014,(05):805.
[5]刘 岩,刘瑞宝,王 平,等. 经导管植入125I放射性粒子治疗肝癌伴门静脉癌栓19例[J].介入放射学杂志,2014,(01):35.
 LIU Yan,LIU Rui? bao,WANG Ping,et al. Percutaneous transcatheter implantation of 125iodine seeds for the treatment of liver cancer associated with portal vein tumor thrombus: initial experience in 19 cases[J].journal interventional radiology,2014,(05):35.
[6]贾 佳,祁兴顺,韩国宏. 肝动脉化疗栓塞在肝细胞肝癌合并门静脉癌栓患者中的应用[J].介入放射学杂志,2014,(04):352.
 JIA Jia,QI Xing-Shun,HAN Guo-hong.. Application of transarterial chemoembolization in treating hepatocellular carcinoma associated with portal vein tumor thrombus[J].journal interventional radiology,2014,(05):352.
[7]任海涛,李任飞,王月东. 原发性肝癌合并门静脉癌栓的治疗进展[J].介入放射学杂志,2013,(11):965.
 REN Hai? tao,LI Ren? fei,WANG Yue? dong.. Recent advances in the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J].journal interventional radiology,2013,(05):965.
[8]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
 XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib: initial experience in 23 cases[J].journal interventional radiology,2014,(05):449.
[9]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
 ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma: analysis of the prognosis and survival[J].journal interventional radiology,2014,(05):435.
[10]尹立楠,刘 岩,刘瑞宝.经导管植入放射性125I粒子治疗门静脉癌栓1例[J].介入放射学杂志,2015,(04):295.
 YIN Li nan,LIU Yan,LIU Rui bao.Transcatheter implantation of 125I seeds for the treatment of portal vein tumor thrombus: report of one case[J].journal interventional radiology,2015,(05):295.
[11]贾中芝,顾晓诚,蒋国民.门静脉癌栓分型对肝细胞性肝癌治疗方法的选择及患者预后的影响 [J].介入放射学杂志,2017,(10):944.
 JIA Zhongzhi,GU Xiaocheng,JIANG Guomin.The application of portal vein tumor thrombus classification in selecting therapeutic method for HCC patients and in estimating the prognosis[J].journal interventional radiology,2017,(05):944.

备注/Memo

备注/Memo:
(收稿日期:2017-10-17)
(本文编辑:边 佶)
更新日期/Last Update: 2018-05-11